T1	PROC 46 61	Estudio Clínico
#1	AnnotatorNotes T1	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T2	PROC 67 115	evaluar la Seguridad, Inmunogenicidad y Eficacia
T3	PROC 267 371	Estudio clínico multicéntrico de fase III estratificado, aleatorizado, con observador ciego y controlado
T4	PROC 882 896	Consentimiento
#2	AnnotatorNotes T4	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T5	PROC 377 431	evaluar la seguridad, la inmunogenicidad y la eficacia
T6	CHEM 439 458	vacuna tetravalente
T7	CHEM 478 487	adyuvante
#4	AnnotatorNotes T7	C0001551; Immunologic Adjuvants; Pharmacologic Substance · Immunologic Factor
T8	CHEM 583 592	adyuvante
#5	AnnotatorNotes T8	C0001551; Immunologic Adjuvants; Pharmacologic Substance · Immunologic Factor
T9	PROC 697 707	Profilaxis
#6	AnnotatorNotes T9	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T10	DISO 803 817	complicaciones
#7	AnnotatorNotes T10	C0009566; Complication; Pathologic Function
T11	DISO 834 839	gripe
#8	AnnotatorNotes T11	C0021400; Influenza; Disease or Syndrome
T12	PROC 1071 1085	procedimientos
#9	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T13	DISO 1155 1162	alergia
#10	AnnotatorNotes T13	C1527304; Allergic Reaction; Pathologic Function
T14	CHEM 123 157	vacuna contra el virus de la gripe
#11	AnnotatorNotes T14	C0021403; Influenza virus vaccine; Immunologic Factor · Pharmacologic Substance
T15	DISO 152 157	gripe
#12	AnnotatorNotes T15	C0021400; Influenza; Disease or Syndrome
T16	CHEM 181 215	vacuna contra el virus de la gripe
#13	AnnotatorNotes T16	C0021403; Influenza virus vaccine; Immunologic Factor · Pharmacologic Substance
T17	DISO 210 215	gripe
#14	AnnotatorNotes T17	C0021400; Influenza; Disease or Syndrome
T18	CHEM 217 224	Fluzone
T19	DISO 510 515	gripe
#15	AnnotatorNotes T19	C0021400; Influenza; Disease or Syndrome
T20	CHEM 529 535	vacuna
#16	AnnotatorNotes T20	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	DISO 573 578	gripe
#17	AnnotatorNotes T21	C0021400; Influenza; Disease or Syndrome
T22	DISO 665 670	gripe
#18	AnnotatorNotes T22	C0021400; Influenza; Disease or Syndrome
T23	DISO 728 733	gripe
#19	AnnotatorNotes T23	C0021400; Influenza; Disease or Syndrome
T24	CHEM 1187 1193	vacuna
#20	AnnotatorNotes T24	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T25	Date 13 17	2012
T26	LIVB 238 243	niños
#21	AnnotatorNotes T26	C0008059; Child; Age Group
T27	LIVB 498 515	virus de la gripe
#22	AnnotatorNotes T27	C0029341; Orthomyxoviridae; Virus
T28	LIVB 561 578	virus de la gripe
#23	AnnotatorNotes T28	C0029341; Orthomyxoviridae; Virus
T29	Neg_cue 579 582	sin
T30	LIVB 596 601	niños
#24	AnnotatorNotes T30	C0008059; Child; Age Group
T31	Age 602 621	de ≥ 6 a < 72 meses
T32	LIVB 653 670	Virus de la gripe
#25	AnnotatorNotes T32	C0029341; Orthomyxoviridae; Virus
T33	LIVB 716 733	virus de la gripe
#26	AnnotatorNotes T33	C0029341; Orthomyxoviridae; Virus
T34	LIVB 762 767	Niños
#27	AnnotatorNotes T34	C0008059; Child; Age Group
T35	LIVB 770 775	niñas
#28	AnnotatorNotes T35	C0008059; Child; Age Group + C0870604; Female child; Age Group
T36	Spec_cue 793 802	riesgo de
T38	Age 841 870	de ≥ 6 meses hasta < 72 meses
T39	LIVB 970 976	sujeto
#29	AnnotatorNotes T39	C0681850; Study Subject; Group
T40	LIVB 980 987	Sujetos
#30	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	LIVB 1031 1037	sujeto
#31	AnnotatorNotes T41	C0681850; Study Subject; Group
T42	LIVB 1127 1134	Sujetos
#32	AnnotatorNotes T42	C0681850; Study Subject; Group
T37	LIVB 946 965	tutor(es) legal(es)
#33	AnnotatorNotes T37	C4288823; Legal Representative for the Study; Human
T43	LIVB 931 945	progenitor(es)
#34	AnnotatorNotes T43	C0030551; parent; Family Group
T44	LIVB 992 1006	progenitor(es)
#35	AnnotatorNotes T44	C0030551; parent; Family Group
T45	LIVB 1007 1026	tutor(es) legal(es)
#36	AnnotatorNotes T45	C4288823; Legal Representative for the Study; Human
#37	AnnotatorNotes T3	C0282461; Phase 3 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C1514983; Stratification; Research Activity + C0150108; Blinded; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity
#38	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity + C4054739; Immunogenicity Study; Research Activity
#39	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity + C4054739; Immunogenicity Study; Research Activity
#40	AnnotatorNotes T18	C0720492; Fluzone; Pharmacologic Substance · Immunologic Factor
A1	Population_data T26 Age
A2	Assertion T8 Negated
A3	Population_data T30 Age
A4	Population_data T34 Age
A5	Population_data T35 Age
A6	Assertion T10 Speculated
A7	Status T13 History_of
R1	Experiences Arg1:T26 Arg2:T14	
R2	Experiences Arg1:T26 Arg2:T16	
R3	Experiences Arg1:T26 Arg2:T18	
R4	Combined_with Arg1:T6 Arg2:T7	
R5	Combined_with Arg1:T20 Arg2:T8	
R6	Negation Arg1:T29 Arg2:T8	
R7	Has_Age Arg1:T30 Arg2:T31	
R8	Experiences Arg1:T30 Arg2:T6	
R9	Experiences Arg1:T30 Arg2:T20	
R10	Before Arg1:T9 Arg2:T23	
T46	LIVB 140 157	virus de la gripe
#3	AnnotatorNotes T46	C0029341; Orthomyxoviridae; Virus
T47	LIVB 198 215	virus de la gripe
#41	AnnotatorNotes T47	C0029341; Orthomyxoviridae; Virus
R11	Causes Arg1:T46 Arg2:T15	
R12	Causes Arg1:T47 Arg2:T17	
R13	Causes Arg1:T27 Arg2:T19	
R14	Causes Arg1:T28 Arg2:T21	
R15	Causes Arg1:T33 Arg2:T23	
R16	Causes Arg1:T32 Arg2:T22	
R17	Speculation Arg1:T36 Arg2:T10	
R20	Has_Age Arg1:T35 Arg2:T38	
R21	Has_Age Arg1:T34 Arg2:T38	
R18	Before Arg1:T11 Arg2:T10	
T48	Quantifier_or_Qualifier 776 781	sanos
#42	AnnotatorNotes T48	C3898900; Healthy; Qualitative Concept
R19	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T48	
R22	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T48	
R23	Experiences Arg1:T41 Arg2:T12	
R24	Experiences Arg1:T40 Arg2:T12	
T49	Observation 1038 1085	capaces de cumplir con todos los procedimientos
#43	AnnotatorNotes T49	C0582784; Able to comply with treatment; Finding | C0582783; Ability to comply with treatment; Finding
R25	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T49	
R27	Experiences Arg1:T42 Arg2:T13	
R28	Causes Arg1:T24 Arg2:T13	
T50	Observation 788 802	alto riesgo de
#44	AnnotatorNotes T50	C0332167; High risk of; Finding
R29	Experiences Arg1:T35 Arg2:T50	
R30	Experiences Arg1:T34 Arg2:T50	
R31	Before Arg1:T50 Arg2:T10	
R32	Experiences Arg1:T34 Arg2:T10	
R33	Experiences Arg1:T35 Arg2:T10	
R34	Experiences Arg1:T34 Arg2:T11	
R35	Experiences Arg1:T35 Arg2:T11	
R26	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T49	
R36	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T49	
R37	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T49	
#45	AnnotatorNotes T6	C4318638; Quadrivalent Influenza Vaccine; Pharmacologic Substance
A8	Experiencer T26 Patient
A9	Experiencer T30 Patient
A10	Experiencer T34 Patient
A11	Experiencer T35 Patient
A12	Experiencer T43 Family_member
A13	Experiencer T37 Other
A14	Experiencer T39 Patient
A15	Experiencer T40 Patient
A16	Experiencer T44 Family_member
A17	Experiencer T45 Other
A18	Experiencer T41 Patient
A19	Experiencer T42 Patient
